See today's BioWorld Asia
To read the full story, subscribe or sign in.

Inmagene gains rights to Syk inhibitor fostamatinib in Chinese markets

Aug. 17, 2021
By Gina Lee
Inmagene Biopharmaceuticals Co. Ltd. has licensed rights from Kissei Pharmaceutical Co. Ltd. to develop and commercialize the spleen tyrosine kinase (Syk) inhibitor fostamatinib for all potential indications in China.
BioWorld Asia Deals and M&A Hematologic China